OTCMKTS:BPSR Organicell Regenerative Medicine (BPSR) Stock Forecast, Price & News $0.01 0.00 (0.00%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.0112▼$0.012050-Day Range$0.0085▼$0.015052-Week Range$0.04▼$0.63Volume32,465 shsAverage Volume3.31 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About Organicell Regenerative Medicine (OTCMKTS:BPSR) StockBiotech Products Services & Research, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development of biological therapeutics for the treatment of degenerative diseases and to provide other related services. The firm also focuses on processing, distribution and supply of biologically processed cellular and tissue-based products developed from internally based research and development activities and also provides healthcare, anti-aging, and regenerative services. The company was founded by John Goodhew, Albert Mitrani and Maria Ines Mitrani on August 9, 2011 and is headquartered in Miami, FL.Read More Receive BPSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organicell Regenerative Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address BPSR Stock News HeadlinesMay 5, 2023 | marketwatch.comGlobal Regenerative Medicine Market [2023-2030] | Latest Trends and Insights | Market to Reach Worth USD 116410 MillionMay 4, 2023 | bbc.comCan regenerative wool make fashion more sustainable?June 10, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...April 6, 2023 | investing.comOrganicell Regenerative Medicine Inc (OCEL)April 5, 2023 | seekingalpha.comOCEL Organicell Regenerative Medicine, Inc.March 29, 2023 | marketwatch.comRegenerative Medicine Market Trends for Future Success 2023-2028March 29, 2023 | marketwatch.comRegenerative Medicine Market 2023: Growing Opportunities by 2028March 18, 2023 | finance.yahoo.comRegenerative Medicine Market Report 2023-2033June 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!February 22, 2023 | finance.yahoo.comMount Vernon, IN Regenerative Medicine Procedures Launched By NuYou TherapiesJanuary 17, 2023 | marketwatch.comRegenerative Medicine Market Regional Outlook & Size Projections with SWOT Analysis to Witness Rapid Growth 2026January 14, 2023 | finance.yahoo.comRegenerative Medicine Market to Touch USD 41.4 Billion by 2028 owing to Rising Chronic Medical AilmentsJanuary 14, 2023 | marketwatch.comRegenerative Medicine for Cartilage Market Industry Expansion Strategies till 2028 with SWOT & RISK AnalysisJanuary 14, 2023 | wsj.comOrganicell Regenerative Medicine Inc.January 11, 2023 | finance.yahoo.comThe Center for Regenerative Medicine Offers State-of-the-Art Non Surgical Solutions for Arthritic ConditionsJanuary 7, 2023 | finance.yahoo.comRegenerative Medicine Market worth $40.6 billion by 2027 - Exclusive Report by MarketsandMarkets™November 22, 2022 | finance.yahoo.comOTCMKTS : OCEL 📋 Organicell Starts Enrolling Long COVID Trial 😷November 17, 2022 | ca.finance.yahoo.comOrganicell Starts Enrolling Long COVID TrialNovember 17, 2022 | yahoo.comCan This Company’s Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?November 14, 2022 | markets.businessinsider.comEQS-News: Can This Companys Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?November 14, 2022 | benzinga.comCan This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?November 10, 2022 | benzinga.comIs It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?October 19, 2022 | sg.finance.yahoo.comOrganicell Regenerative Medicine, Inc. (OCEL)October 13, 2022 | benzinga.comOrganicell Regenerative Medicine Broadens Access to Valued Business Expertise and Relationship With New Additions to Board of DirectorsSeptember 9, 2022 | seekingalpha.comOrganicell Regenerative Medicine secures additional $11M financing for clinical trial enrollmentSeptember 9, 2022 | apnews.comOrganicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial EnrollmentAugust 30, 2022 | finance.yahoo.comOrganicell Regenerative Medicine, Inc. Engages Law Firm McDermott Will & EmerySee More Headlines BPSR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BPSR CUSIPN/A CIK1557376 Webwww.bespoketricycles.com Phone(888) 963-7881FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesAlbert MitraniPresident, CEO, COO, Secretary & TreasurerIan T. BothwellChief Financial Officer & DirectorMaria Ines MitraniDirector, Chief Science Officer & Vice PresidentGeorge Craig ShapiroDirector & Chief Medical OfficerKey Competitors3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAinosNASDAQ:AIMDWView All Competitors BPSR Stock - Frequently Asked Questions How have BPSR shares performed in 2023? Organicell Regenerative Medicine's stock was trading at $0.0199 at the beginning of 2023. Since then, BPSR shares have decreased by 40.7% and is now trading at $0.0118. View the best growth stocks for 2023 here. What other stocks do shareholders of Organicell Regenerative Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organicell Regenerative Medicine investors own include Ciena (CIEN), Orbit Garant Drilling (OGD), Royal Caribbean Cruises (RCL), Synergy Pharmaceuticals (SGYP), Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and Abacus Property Group (ABP). What is Organicell Regenerative Medicine's stock symbol? Organicell Regenerative Medicine trades on the OTCMKTS under the ticker symbol "BPSR." How do I buy shares of Organicell Regenerative Medicine? Shares of BPSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organicell Regenerative Medicine's stock price today? One share of BPSR stock can currently be purchased for approximately $0.01. How can I contact Organicell Regenerative Medicine? Organicell Regenerative Medicine's mailing address is 4045 Sheridan Avenue,Suite 239, MIAMI, FL 33140, United States. The official website for the company is www.bespoketricycles.com. The company can be reached via phone at (888) 963-7881. This page (OTCMKTS:BPSR) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organicell Regenerative Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.